PCSK9 INHIBITION AUGMENTS THE THERAPEUTIC EFFECT OF EZETIMIBE IN LOWERING INTESTINAL APOLIPOPROTEIN B LIPOPROTEIN PRODUCTION

被引：0
|
作者：
Melone, M.
Davis, H. R.
Ai, X.
Neff, D. R.
Fazio, S.
Rashid, S.
机构：
来源：
CANADIAN JOURNAL OF CARDIOLOGY | 2013年 / 29卷 / 10期
关键词：
D O I：
10.1016/j.cjca.2013.07.649
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
732
引用
收藏
页码：S378 / S378
页数：1
相关论文
共 50 条
  • [1] PCSK9 Inhibition Augments the Therapeutic Effect of Ezetimibe in Lowering Intestinal Apolipoprotein B Lipoprotein Production
    Rashid, Shirya
    Davis, Harry R.
    Ai, Xi
    Neff, David R.
    Fazio, Sergio
    CIRCULATION, 2013, 128 (22)
  • [2] PCSK9 INHIBITION AUGMENTS THE THERAPEUTIC EFFECT OF EZETIMIBE IN LOWERING INTESTINAL APOLIPOPROTEIN B LIPOPROTEIN PRODUCTION
    Rashid, S.
    Melone, M.
    Tavori, H.
    Guinzioni, I.
    Neff, D.
    Fazio, S.
    ATHEROSCLEROSIS, 2014, 235 (02) : E258 - E258
  • [3] PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate
    Croyal, Mikael
    Thi-Thu-Trang Tran
    Blanchard, Rose Helene
    Le Bail, Jean-Christophe
    Villard, Elise F.
    Poirier, Bruno
    Aguesse, Audrey
    Billon-Crossouard, Stephanie
    Ramin-Mangata, Stephane
    Blanchard, Valentin
    Nativel, Brice
    Chemello, Kevin
    Khantalin, Ilya
    Thedrez, Aurelie
    Janiak, Philip
    Krempf, Michel
    Boixel, Christophe
    Lambert, Gilles
    Guillot, Etienne
    CLINICAL SCIENCE, 2018, 132 (10) : 1075 - 1083
  • [4] The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe
    Fazio, Sergio
    ATHEROSCLEROSIS SUPPLEMENTS, 2015, 17 : 23 - 26
  • [5] LDL LOWERING EFFECT OF PCSK9 INHIBITION IS REDUCED IN WOMEN
    Myasoedova, V.
    Rimbert, A.
    Camera, M.
    Le May, C.
    Capoulade, R.
    Cariou, B.
    Poggio, P.
    ATHEROSCLEROSIS, 2023, 379
  • [6] LDL lowering effect of PCSK9 inhibition is reduced in women
    Myasoedova, Veronika A.
    Rimbert, Antoine
    Camera, Marina
    Le May, Cedric
    Capoulade, Romain
    Cariou, Bertrand
    Poggio, Paolo
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2023, 9 (04) : 337 - 342
  • [7] The complexity of lipoprotein (a) lowering by PCSK9 monoclonal antibodies
    Lambert, Gilles
    Thedrez, Aurelie
    Croyal, Mikael
    Ramin-Mangata, Stephane
    Couret, David
    Diotel, Nicolas
    Nobecourt-Dupuy, Estelle
    Krempf, Michel
    LeBail, Jean Christophe
    Poirier, Bruno
    Blankenstein, Jorg
    Villard, Elise F.
    Guillot, Etienne
    CLINICAL SCIENCE, 2017, 131 (04) : 261 - 268
  • [8] Elusive Therapeutic Effect of PCSK9 Inhibitors on Lipoprotein(a) Levels
    Sbrana, Francesco
    Bigazzi, Federico
    Dal Pino, Beatrice
    Toma, Maddalena
    Ripoli, Andrea
    Sampietro, Tiziana
    THERAPEUTIC APHERESIS AND DIALYSIS, 2019, 23 (04) : 385 - 386
  • [9] Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
    Wojcik, Cezary
    REVIEWS IN HEALTH CARE, 2016, 7 (01) : 17 - 25
  • [10] APOLIPOPROTEIN E: THE LINK BETWEEN PCSK9 AND LIPOPROTEIN (A)?
    Nobecourt, E.
    Blanchard, V.
    Crossouard, S.
    Aguesse, A.
    Krempf, M.
    Croyal, M.
    ATHEROSCLEROSIS, 2019, 287 : E37 - E37
12345